Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) have received an average recommendation of “Buy” from the fifteen brokerages that are covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $20.00.
SCMP has been the subject of several analyst reports. ValuEngine raised shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 7th. Maxim Group reissued a “buy” rating and issued a $23.00 price target on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. Instinet initiated coverage on shares of Sucampo Pharmaceuticals in a report on Tuesday, December 19th. They set a “buy” rating and a $43.00 price objective for the company. Mizuho lifted their price objective on shares of Sucampo Pharmaceuticals from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, December 8th. Finally, Nomura reaffirmed a “neutral” rating and set a $18.00 price objective on shares of Sucampo Pharmaceuticals in a report on Friday, January 26th.
Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) remained flat at $$18.00 during trading hours on Wednesday. 956,100 shares of the company’s stock were exchanged, compared to its average volume of 2,557,332. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 1 year low of $9.30 and a 1 year high of $18.75. The stock has a market capitalization of $839.46, a P/E ratio of -5.37, a P/E/G ratio of 5.06 and a beta of 1.38.
In other news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now directly owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.13% of the company’s stock.
A number of institutional investors have recently bought and sold shares of SCMP. Point72 Asset Management L.P. bought a new stake in Sucampo Pharmaceuticals in the third quarter worth $21,989,000. Alpine Associates Management Inc. bought a new stake in Sucampo Pharmaceuticals in the fourth quarter worth $26,845,000. Renaissance Technologies LLC lifted its stake in Sucampo Pharmaceuticals by 49.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,957,600 shares of the biopharmaceutical company’s stock worth $35,139,000 after purchasing an additional 651,900 shares during the last quarter. Nexthera Capital LP bought a new stake in Sucampo Pharmaceuticals in the fourth quarter worth $9,163,000. Finally, Two Sigma Investments LP lifted its stake in Sucampo Pharmaceuticals by 1,013.8% in the fourth quarter. Two Sigma Investments LP now owns 548,672 shares of the biopharmaceutical company’s stock worth $9,849,000 after purchasing an additional 499,409 shares during the last quarter. 67.09% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Sucampo Pharmaceuticals, Inc. (SCMP) Receives $20.00 Average PT from Brokerages” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://ledgergazette.com/2018/02/19/sucampo-pharmaceuticals-inc-scmp-receives-20-00-average-pt-from-brokerages.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.